Suppr超能文献

研究白蛋白对 Nagase 遗传性无白蛋白血症大鼠中匹伐他汀和华法林肝脏摄取的影响。

Investigating the Impact of Albumin on the Liver Uptake of Pitavastatin and Warfarin in Nagase Analbuminemic Rats.

机构信息

Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California

Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California.

出版信息

Drug Metab Dispos. 2019 Nov;47(11):1307-1313. doi: 10.1124/dmd.119.088278. Epub 2019 Sep 6.

Abstract

Albumin has been suggested to enhance the hepatic uptake of organic anion-transporting polypeptide (Oatp) substrates in various in vitro as well as liver perfusion models. However, it is not known whether the interplay between albumin and Oatp substrates is an experimental artifact or if this interaction occurs in vivo. The objective of this work was to investigate the hepatic uptake of warfarin and pitavastatin, which are both extensively bound to albumin but only pitavastatin being an Oatp substrate. Experiments were conducted in Nagase analbuminemic rats (NAR) which exhibit reduced albumin levels compared with F344 (wild type, WT). The fraction unbound ( ) was 140- and 10-fold greater in NAR plasma for warfarin and pitavastatin, respectively, whereas no meaningful differences were observed with tissue binding. In vitro, pitavastatin uptake into hepatocytes reconstituted in WT plasma was 17- and 3-fold greater than when reconstituted in buffer or NAR plasma, respectively. In vivo, the free tissue-to-free plasma ratios ( ) from brain and liver in intact WT and NAR were not significantly different for warfarin. Contrarily, liver of pitavastatin was 6-fold higher in WT animals, which corresponded to a 2.3-fold reduction in free plasma and 2.6-fold increase in free liver exposure. These results suggest that the enhanced hepatic uptake by albumin is not necessarily an experimental artifact but is also a relevant phenomenon in vivo. This work raises the possibility that other plasma proteins may also effect the function of additional drug transporters, and that modulating plasma protein binding may exhibit meaningful clinical relevance in the disposition of drugs. SIGNIFICANCE STATEMENT: The interplay between albumin and Oatp substrates has been reported in hepatocytes and in liver perfusion studies, but the in vivo relevance of this interaction has yet to be elucidated. Using NAR and its corresponding WT animal, this study demonstrates that albumin may indeed enhance the hepatic uptake of pitavastatin in intact animals. In vivo demonstration of this interplay not only provides further justification for continued investigation into this particular mechanism but also raises the possibility that other plasma proteins may affect additional drug transporters and that modulating plasma protein binding may exhibit meaningful clinical relevance in the disposition of drugs.

摘要

白蛋白已被证实可增强有机阴离子转运多肽(Oatp)底物在各种体外和肝脏灌流模型中的肝摄取。然而,白蛋白与 Oatp 底物之间的相互作用是实验性假象,还是这种相互作用发生在体内,目前尚不清楚。本研究的目的是研究华法林和匹伐他汀的肝摄取,这两种药物均与白蛋白广泛结合,但只有匹伐他汀是 Oatp 底物。实验在 Nagase 无白蛋白血症大鼠(NAR)中进行,与 F344(野生型,WT)相比,NAR 白蛋白水平降低。华法林和匹伐他汀在 NAR 血浆中的未结合分数( )分别高 140 倍和 10 倍,而组织结合无明显差异。在体外,匹伐他汀在 WT 血浆中重建的肝细胞摄取量比在缓冲液或 NAR 血浆中重建的分别高 17 倍和 3 倍。在体内,完整 WT 和 NAR 脑和肝的游离组织-游离血浆比( )对华法林无显著差异。相反,匹伐他汀在 WT 动物中的肝摄取 高 6 倍,这对应于游离血浆减少 2.3 倍,游离肝脏暴露增加 2.6 倍。这些结果表明,白蛋白增强的肝摄取不一定是实验性假象,也是体内的一种相关现象。这项工作提出了一种可能性,即其他血浆蛋白也可能影响其他药物转运体的功能,而调节血浆蛋白结合可能对药物处置具有重要的临床意义。意义陈述:白蛋白与 Oatp 底物之间的相互作用已在肝细胞和肝脏灌注研究中报道,但这种相互作用的体内相关性尚未阐明。本研究使用 NAR 及其相应的 WT 动物,证明白蛋白确实可以增强完整动物中匹伐他汀的肝摄取。体内相互作用的证明不仅为进一步研究这一特殊机制提供了更多依据,还提出了一种可能性,即其他血浆蛋白可能影响其他药物转运体,调节血浆蛋白结合可能对药物处置具有重要的临床意义。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验